Hematology Oncology Market Size, Share, By Hematology Product (Hematology Cell Counters, Slide Strainers, Centrifuges, Hematology Analyzers, Hematology Reagents, and Flow Cytometers), Oncology Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, and Others), Oncology Indication (Leukemia, Lymphoma, and Multiple Myeloma), End-User (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, and Others) and Region - Trends, Analysis, and Forecast till 2035

• The target market is expected to increase at a rate of USD 37.3 Billion, by 2035.
• In 2024, the hematology oncology market size was worth USD 11.1 Billion.
• The market is growing at a CAGR of 12.9%.

Hematology oncology is a medical specialty that focuses on the diagnosis, treatment, and prevention of cancer that affects the blood and bone marrow system. It includes, leukemia, lymphoma, and multiple myeloma disorders along with various cancerous blood disorders. The various healthcare providers are focusing on the development, production and sale of drugs and diagnostic tests used to treat blood cancer and blood related disorders. The growing cancer prevalence, and advancement in precision medicine, anticipated to hematology oncology market growth.

Impact of AI on Hematology Oncology Market:

Artificial Intelligence (AI) significantly impacts hematology oncology market by enabling more accurate personalized diagnoses, and predicting treatment outcomes with greater precision. AI algorithms can analyze medical images, such as bone marrow aspires, blood smears, and different types of blood cancer with high accuracy and sensitivity. By analyzing large datasets of patient information, AI can predict individual patient response to predict individual’s different treatment plan.

Key Drivers of Target Market:

Advancements in Treatments for Cancer is Expected to Drive Market Growth

The advancement in treatment therapies include targeted therapies, immunotherapies such as, immune checkpoints inhibitors and CAR-T cell therapy and nanotechnology-based drug delivery system. These advanced therapies increase effectiveness against specific cancer cells, reduces side effects of drugs and give personalized treatment approaches, and also lead to improve patient outcomes with improved life. New therapies are constantly tested through clinical trials, providing access of life-saving treatments for patients.

• For instance, January 2025, Bristol Myers, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi. A CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

Rising Incidence of Hematologic Cancer to Boost Market Growth

Rising prevalence of lymphoma and myeloma and other blood disorders lead to technological advancements in therapies. The hematology oncology market growth is fueled by the molecular approaches to address issues with blood cancer prognosis, course of therapy and diagnosis techniques. The changing environment factors and lifestyle risk factors is contributing to more people being diagnosed with hematologic cancer, resulting to expand target market share.

• For instance, according to data published by Leukemia & Lymphoma Society, approximately every 3 minutes, one person in the U.S. is diagnosed with leukemia, lymphoma or myeloma. An estimated combined total of 187,740 people in the U.S. are expected to be diagnosed with leukemia, lymphoma or myeloma in 2024. New cases of leukemia, lymphoma and myeloma are expected to account for 9.4% of the estimated 2,001,140 new cancer cases that was diagnosed in the U.S. in 2024.

Restraints:

High Treatment Costs May Impede Target Market Growth

The high cost of advanced hematology oncology treatments and therapies lead to major financial burden on both patient and healthcare systems. The increasing incidence of hematologic cancer increased the need for treatments, which both developed and developing countries face significant burden of budgets making them difficult for therapies.

• Counterbalance Statements: Government health programs and private health insurance companies are increasingly covering the high costs of advanced therapies and developing more cost-effective and efficient therapies for hematology oncology cancer treatment.

Opportunities & Market Trends:

 Increasing Research and Development Field Fuels the Market Expansion

Increasing research and development field fuels the market expansion by making advancements in hematologic cancer by developing new drugs, therapies, and diagnostic tools. Researchers are developing new diagnostic tools to identify specific genetic mutation and biomarkers in cancer cells. Researchers are focusing on integration of AI-tools to predict patient outcomes, optimize diagnosis, and to monitor specific therapies on patient. These therapies are used in the treatment of various blood disorder and inventing new therapies for better treatment, resulting to drive hematology oncology market growth in coming years.

The hematology oncology is segmented into hematology product, oncology drug class type, oncology indication, end-user, and region.

Hematology Product:

By hematology product, the target market is categorized into hematology cell counters, slide strainers, centrifuges, hematology analyzers, hematology reagents, and flow cytometers. The hematology analyzers holds the largest hematology oncology market share due to the increasing demand for hematology advanced instrument to diagnose and monitor blood disorder. Hematology analyzers are used to detect and measure blood cells, including white blood cells, red blood cells, and platelets, which are important for testing blood cancer disorder, resulting to drive hematology oncology market growth in product segment manner.

• For instance, in May 2020, Backman Coulter launched their new product, DxH 690T hematology analyzer in the U.S. designed to streamline workflow and minimize downtime in mid-volume laboratories. The DxH 690T is aimed to improve turnaround time by reducing procedural steps and manual errors. Its advanced feature is designed to help emergency department physician to identify adult patients with sepsis.

Oncology Drug Class Type:

By oncology drug class type, the focused market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others. The chemotherapy holds the largest hematology oncology market share due to its wide usage in treatment of various types of cancer. In hematologic cancer, chemotherapy provide a cure, especially when it is combined with other treatments such as, stem cell transplants. Chemotherapy can be combined with other therapies, such as targeted therapies, immunotherapy, and radiation to enhance treatment affectivity, help to drive hematology oncology market growth.

Oncology Indication:

Hematology oncology by oncology indication divided into leukemia, lymphoma, and multiple myeloma. The leukemia segment dominates the target market due to the increasing prevalence of leukemia disorders particularly in children. Thus, the increasing awareness among the people for personalized medicine and advanced diagnostic tests and treatment options in hematology oncology field drives the target market growth. 

• For instance, in June 2020, Roche received FDA approval for cobas EZH2 Mutation Test as companion diagnostic for TAZVERIK, which is developed by Epizyme, Inc. This molecular test detects abnormalities in the Enhancer of Zeste Homolog 2 (EZH2), gene in patients with follicular lymphoma for the treatment with TAZVERIK, a cancer drug that acts as a selective EZH2 gene inhibitor. This new technique is aimed to provide clinicians and patients for rapid and reliable result of follicular lymphoma to determine best treatment options.

End-User:

By end-user, the hematology oncology market is segmented into hospitals, diagnostic laboratories, academic & research institutes, and others. The hospitals segment holds a dominant position in the target market as it is considered as a primary source for cancer diagnosis and treatment. Hospitals are equipped with necessary infrastructure, trained medical professionals, and technologies to handle advanced treatments and manage associated therapies of particular diseases.

Region:

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This is the dominating region for the hematology oncology market due to the increasing prevalence of leukemia, lymphoma, multiple myeloma, and other blood related disorders. The increasing investment in healthcare infrastructure, presence of large number of research center, hospitals, and oncology centers in the U.S., resulting to drive hematology oncology market in this region.

• For instance, according to data published by Leukemia & Lymphoma Society, an estimated 437,337 people are living with leukemia in the U.S. and 59,610 people are expected to be diagnosed with leukemia. An estimated 159,867 people are living with Hodgkin lymphoma, and 722,631 people are living with non-Hodgkin lymphoma. The age-adjusted incidence rate of myeloma in non-Hispanic (NH) Black males and females (14.5 per 100,000) was 2.3 times greater than that of NH white males and females (6.4 per 100,100)

Asia Pacific: This is the expected as growing region for the target market, due to rapid healthcare improvements, and increasing cancer awareness in countries, such as China, Japan, and India, are creating unique opportunities for treatment development. Governments are focusing on improving healthcare infrastructure and rising investment in cancer care, resulting to drive hematology oncology market in upcoming years.

Hematology Oncology Market Report Scope:

Segmentation:

By Hematology Product:

• Haematology Cell Counters
• Slide Strainers
• Centrifuges
• Haematology Analyzers
• Haematology Reagents
• Flow Cytometers

By Oncology Drug Class Type:

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Others

By Oncology Indication:

• Leukemia
• Lymphoma
• Multiple Myeloma

By End-User:

• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes
• Others

 By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the hematology oncology market include Bristol-Myers Squibb Company, AstraZeneca, and others. These key players are focusing on improving on research and development, innovative strategies, new product launches, strategic partnerships and acquisitions to enhance product offering through collaborations.

• Bristol-Myers Squibb Company
• AstraZeneca
• Abbott
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• Gilead Sciences, Inc
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Alexion Pharmaceuticals, Inc.
• Beam Therapeutics
• Miltenyi Biotec
• Astellas Pharma Inc
• BioNTech SE.
• Sanofi
• Disc Medicine

View a additional list of companies in the Hematology Oncology Market

• In January 2025, Immuneel Therapeutics, the Bengaluru-based cell and gene therapy company, had launched India's second CAR-T cell therapy called as, Qartemi to treat patients with B-cell Non-Hodgkin Lymphoma (B-NHL), an aggressive form of blood cancer. The Chimeric antigen receptor (CAR-T) therapy harnesses a patient's T-cell or immune cells to target and eliminate cancer, offering a new paradigm for treating aggressive blood cancers when other treatments like chemotherapy have not been effective.
• In January 2024, HORIBA Medical launched the new HELO 2.0 high throughput automated hematology platform which is CE-IVDR approved. HELO 2.0 was the advanced hematology technologies to offer flexible, high throughput, high quality analytical performance. HELO 2.0’s data, aimed for tube management, waste, blood smear and digitalization management capability, addresses all pre-, post- and analytical needs, with optimizing turnaround time (TAT), floor space and reagent storage.

Analyst View:

The increasing incidence of myeloma & lymphoma and proliferation of sequencing techniques, including targeted therapy, immunotherapy, is aimed to enhance the accuracy and accessibility of molecular diagnostics for hematologic cancer. The increasing research & development and rising investment of key players for innovation in technologies leads toward the growth of hematology oncology market.

More Related Reports

Immuno-Oncology Drugs Market
Interventional Oncology Devices Market
Hemato Oncology Testing Market
Oncology Biosimilar Treatment Market
Oncology Drugs Market